Skip to main content

Share story

Infrastructure

DayOne Data Centers Nears Confidential U.S. IPO Filing

DayOne Data Centers Nears Confidential U.S. IPO Filing Image: Primary
Singapore-based DayOne Data Centers is nearing a confidential filing for a U.S. initial public offering. Bloomberg reports the development. The company has been tied to the global buildout of large-scale data center capacity. Investors view this asset class as central to the AI spending cycle. Public markets are starting to treat AI data centers as strategic infrastructure rather than ordinary real estate or commodity hosting assets. Pricing power in the sector is tied to chips, power access, land, and network connectivity. This shift could direct more capital to AI infrastructure developers across Asia, Europe, and North America. It also positions compute availability as a financing topic in its own right. Investors are increasingly backing foundational elements of the AI economy alongside model and application companies.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Bloomberg and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.